Exciting Link: Exalgo & N-Type Ca Channel Research
When I read the following paragraph, I was stunned.
Has anyone yet understood the link between Exalgo and N-type Ca Channel research? I doubt any of you have.
Because it's right in front of our faces "combinational effects of μ-opioids with Ca++ channel blockers").
Many here have wondered why Neuromed was so hot to get its hands on CombinatoRx cHTS platform -- NOW YOU KNOW IF YOU KNOW WHAT I QUOTE BELOW MEANS--I hope you won't dismiss the following paragraph--
"The mechanistic differences in μ-opioid analgesic effects also point to potential differences in susceptibility of Aδ and C fiber-mediated nociception to combinational effects of μ-opioids with Ca++ channel blockers. N-type Ca++ channels appear to be involved in conveying nociceptive messages into the central from the peripheral nervous system (13). Consistent with this, N-type Ca++ channels are highly concentrated in central terminals of primary afferents (14), and N-type Ca++ channel blockers have analgesic effects alone (15,16) and in combination with μ-opioids (17–19). Large doses of N-type Ca++ channel blockers given alone are generally necessary to produce significant analgesia, which may produce side effects (15), indicating a relatively small therapeutic index. In combination with opioids, however, Ca++ channel blockers appear to produce stronger analgesia (19). The nature of this interaction is not clear, however, in that some investigators have described additive effects (17) whereas others have reported pharmacologic synergy (18,19). These differences may be a result of undescribed differences in the types of afferent activity producing the pain or nociceptive responses under investigation. The purpose of this study was to investigate the effects of an N-type Ca++ channel blocker in a model of nociception in which the contribution of C and Aδ nociceptors has been defined (2,20) as well as to describe potential interactions between the μ-opioid morphine and an N-type Ca++ channel blocker."
This is a 2001 article, but it is interesting, and I think the science is legitimate. There should be some more recent articles out there on the topic though.
I think like Synavive, this is all about combining drugs to reduce or eliminate side effects and enhance efficacy. Sounds great!
You had some weird attacks on this one Lasar. No one said Synavive could cure OA or RA. I had to laugh reading this one. It is clearly an ehanced low dose steroid to reduce inflammation. The steroid side effects are reduced as well. CombinatoRx has been very transparent about what it does, and what it does is worth billions.
Keep it coming Lasar. Great stuff as far as I am concerned.
hi,stocklosar, Could you please stop barking. This is an introduction of a junk paper and you take it as an important investing decision because you don't have any scientific background and know nothing about Ca++ channel. The introduction itself had controversial claim. The paper cited that 'N-type Ca++ channels are highly concentrated in central terminals of primary afferents'. it is absolutely nonsense to link the fact to Morphine which acts upon central nervous system. buddy, it is a stock not your lover...